Data as of May 23
| +0.05 / +1.27%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 16.00, with a high estimate of 16.00 and a low estimate of 16.00. The median estimate represents a +301.00% increase from the last price of 3.99.
The current consensus among 1 polled investment analysts is to Hold stock in Rosetta Genomics Ltd. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.